AU730211B2 - Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents - Google Patents

Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents Download PDF

Info

Publication number
AU730211B2
AU730211B2 AU72982/98A AU7298298A AU730211B2 AU 730211 B2 AU730211 B2 AU 730211B2 AU 72982/98 A AU72982/98 A AU 72982/98A AU 7298298 A AU7298298 A AU 7298298A AU 730211 B2 AU730211 B2 AU 730211B2
Authority
AU
Australia
Prior art keywords
alkyl
phenyl
pyrazol
trifluoromethyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU72982/98A
Other languages
English (en)
Other versions
AU7298298A (en
Inventor
Jaime L Masferrer
Amiram Raz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU7298298A publication Critical patent/AU7298298A/en
Application granted granted Critical
Publication of AU730211B2 publication Critical patent/AU730211B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU72982/98A 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents Ceased AU730211B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
US60/031404 1996-11-19
PCT/US1997/021489 WO1998022101A2 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
AU7298298A AU7298298A (en) 1998-06-10
AU730211B2 true AU730211B2 (en) 2001-03-01

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72982/98A Ceased AU730211B2 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Country Status (19)

Country Link
EP (1) EP0941080A2 (no)
JP (1) JP2001505564A (no)
KR (1) KR20000053362A (no)
CN (1) CN1247470A (no)
AU (1) AU730211B2 (no)
BR (1) BR9713522A (no)
CA (1) CA2270469C (no)
CZ (1) CZ176899A3 (no)
ID (1) ID21979A (no)
IL (1) IL129604A (no)
NO (1) NO992309L (no)
NZ (1) NZ335853A (no)
PL (2) PL194717B1 (no)
RO (1) RO118566B1 (no)
RU (1) RU2268716C2 (no)
SK (1) SK59999A3 (no)
TR (1) TR199901703T2 (no)
UA (1) UA70294C2 (no)
WO (1) WO1998022101A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
EP1158977B1 (en) * 1999-03-10 2005-10-12 G.D. Searle LLC Composition for administering a cyclooxygenase-2 inhibitor to animals
WO2001008693A2 (en) * 1999-07-29 2001-02-08 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
EP1282418B1 (en) * 2000-05-19 2005-08-17 Applied Research Systems ARS Holding N.V. Use of pyrazole derivatives for treating infertility
US6822001B2 (en) 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
WO2004006931A2 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015932A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
GB2283745A (en) * 1993-11-12 1995-05-17 Merck Frosst Canada Inc Pharmaceutically active N-acylindoles
WO1996006840A1 (en) * 1994-08-29 1996-03-07 Merck Frosst Canada Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193609T3 (es) * 1993-11-30 2003-11-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas y su uso como inhibidores de la ciclooxigenasa ii.
ES2191069T3 (es) * 1994-12-21 2003-09-01 Merck Frosst Canada Inc Diaril-2-(5h)-furanonas como inhibidores de cox-2.
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015932A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
GB2283745A (en) * 1993-11-12 1995-05-17 Merck Frosst Canada Inc Pharmaceutically active N-acylindoles
WO1996006840A1 (en) * 1994-08-29 1996-03-07 Merck Frosst Canada Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2

Also Published As

Publication number Publication date
PL191793B1 (pl) 2006-07-31
NZ335853A (en) 2002-02-01
BR9713522A (pt) 2000-03-21
NO992309D0 (no) 1999-05-12
CA2270469C (en) 2007-04-10
AU7298298A (en) 1998-06-10
CZ176899A3 (cs) 1999-10-13
UA70294C2 (en) 2004-10-15
IL129604A (en) 2004-08-31
NO992309L (no) 1999-05-12
KR20000053362A (ko) 2000-08-25
JP2001505564A (ja) 2001-04-24
RU2268716C2 (ru) 2006-01-27
IL129604A0 (en) 2000-02-29
TR199901703T2 (xx) 2000-07-21
CA2270469A1 (en) 1998-05-28
SK59999A3 (en) 2000-01-18
EP0941080A2 (en) 1999-09-15
ID21979A (id) 1999-08-19
RO118566B1 (ro) 2003-07-30
WO1998022101A3 (en) 1998-06-25
PL194717B1 (pl) 2007-06-29
WO1998022101A2 (en) 1998-05-28
CN1247470A (zh) 2000-03-15
PL333370A1 (en) 1999-12-06

Similar Documents

Publication Publication Date Title
US6025353A (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU742645B2 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US5972986A (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1998016227A9 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AU730211B2 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
CA2372912C (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
IL154502A (en) Use of cyclooxygenase-2 inhibitors in the preparation of medicaments for treating angiogenesis-related disorders
NZ517374A (en) Method of using cycloozygenase-2 inhibitors to prevent a neoplasia that produces a prostaglandin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)